What’s Inside: Element Biosciences Raises $277M; Reaffirm Your Commitment to DEI by Signing Our Member Pledge; FNIH Launches Project to Find Biomarkers for Parkinson’s; Update on the IRA’s Drug Price ‘Negotiation’ Program; and more.
|
We’re championing the progress made by California’s life science community and want to hear about your company’s latest scientific breakthrough, investment milestone, or commitment to creating positive change for our industry. Submit your story here for possible inclusion in an upcoming issue.
|
|
What’s Happening at Biocom California
|
|
Over 200 Attend Third Annual Greater LA Life Science Forum
Our third annual Greater LA Life Science Forum on July 18 was sold out for the second year in a row with 200 attendees gathering at the Luxe Sunset Boulevard Hotel. Panelists discussed how Greater LA is poised to become the next “mega-cluster” with an abundance of resources, concentration of higher education institutions and nearly $70 billion in economic output. With the region being one of the most diverse in the world, it is uniquely positioned to support clinical trials and helps address the needs of the most vulnerable. Among the policy presentations were a panel who discussed our work with the City of Pasadena, Senior Director of Economic Policy for Mayor Karen Bass Max Reyes and Supervisor Kathryn Barger’s Health Deputy Anders Corey. The forum was followed by our annual Core by Biocom California Open House and Supplier Showcase.
|
HR Conference for Life Science Now Statewide
Returning this September, our HR Conference for Life Science is a strategic, two-day forum designed to connect HR communities across California, providing valuable insights into the critical issues impacting the industry. We invite HR professionals at life science companies of all sizes to join us September 24–25 in South San Francisco for meaningful networking opportunities and insightful sessions. HR leaders will gain valuable insights from experts through enlightening panel discussions and informative presentations, equipping them with the tools and knowledge to develop a future-ready workforce. Take advantage of early-bird rates and save up to 15% when registering by July 31.
|
Join Us in Accelerating Diversity, Equity and Inclusion
As we continue to amplify diverse voices across the life science industry and facilitate important discussions on effective ways to create an inclusive workforce, we invite our members and partners to sign the Biocom California DEI Pledge. By doing so, you commit to fostering inclusion, breaking down barriers and promoting equity. Now more than ever, it’s vital our industry comes together to advocate for a more just and inclusive society, ensuring that equity and equality are at the forefront of all our efforts.
|
|
|
Industry Intelligence & Member Moments
|
- Artiva upsized its IPO to $167 million, placing 13.9 million shares on the market at $12 per share, and noted that $55 million from the IPO would support the development of its NK cell therapy.
- Element Biosciences raises $277 million in Series D round to support commercialization of its benchtop DNA sequencer and an instrument launch.
- G&L Healthcare Advisors expanded its global reach and service offering by acquiring SmartStep Consulting, an experienced leader in launching products in the German market.
- GSK, Sanofi and others take part in a $21 million public-private project led by the Foundation for the National Institutes of Health to hunt for biomarkers that distinguish Parkinson’s disease from similar conditions.
- IASO Bio received FDA approval of its investigational new drug application for equecabtagene for multiple sclerosis.
- Invitae launched its Unlock Behind the Seizure program, which provides accessible and affordable genetic testing for pediatric epilepsy patients.
- Novartis will partner with Dren Bio to discover and develop new bispecific antibodies for cancer using Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform.
- PacBio’s Revio long-read sequencing system is being used by Novogene to expand the capabilities of its new lab in Munich, Germany.
- Parker Institute for Cancer Immunotherapy invested an additional $125 million into research efforts that accelerate the development of innovative cancer immunotherapies.
- Pfizer’s experimental gene therapy for rare genetic blood-clotting disorder is successful in its late-stage trial, paving the way for a potential approval.
- Sapient expanded its mass spectrometry-based metabolomics and lipidomics services with a commercial standards library of more than 10,000 chemical reference standards to accelerate insights and translation of findings for small molecule biomarker studies.
|
|
|
GO-Biz Now Accepting Applications for $215M in Tax Credits
The California Competes Tax Credit (CCTC) is an income tax credit available to businesses that want to grow in California. Biocom California was a key partner in creating this program and many life science companies have been successful in receiving a tax credit. Starting July 22, applications can be submitted online and are due August 12 at 11:59 p.m. PDT. Application assistance, webinars and additional resources are available on the CCTC website.
|
|
Blueprint San Diego Passes City Council
On July 23, San Diego City Council unanimously passed Blueprint San Diego, the city-initiated update to its general plan, which was last updated in 2008. Biocom California has been supportive of the update given its policy language allowing for additional housing near transit and mixed-use developments that include lab space. However, we became aware during the council meeting that language had been introduced the evening before the meeting related to building electrification. We made it clear during our comments that while we support the plan, any policy changes related to building mandates need further study and stakeholder engagement. This policy will inform City Council’s vote on the UC Plan Update on July 30.
|
|
Bay Area Cities Finalize Business Tax Measures for November Ballot
Redwood City Council finalized language for a Business License Tax ballot initiative to be on the November ballot. The measure includes a fee per employee and a maximum cap of $250,000 (reduced from the original proposal of $500,000) that will be phased in over two years, beginning in 2025. Biocom California was actively engaged and advocating for our members with city staff and community partners. Similarly, South San Francisco City Council voted to approve ballot language for voters to decide whether to reform their Business License Tax. They moved forward with an increase in fee per employee and no maximum cap.
|
|
Biocom California
For over 29 years, Biocom California has helped move the life science industry forward with transformative resources that enable companies to make meaningful connections. With a membership base of over {{{dynamic_content_1600}}} companies, we connect our members to each other so they can collaborate and work stronger and smarter together. We connect organizations to capital investment and purchasing solutions so they can grow faster and work more efficiently. We’re their link to advocacy that fights for innovation and we provide an environment where their business and talent can thrive. Biocom California is how the life science industry gets connected.
|
|
|